Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vaccinex Inc (NQ: VCNX )

5.780 +0.080 (+1.40%)
Streaming Delayed Price Updated: 1:51 PM EDT, May 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vaccinex Inc

< Previous 1 2 Next >
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex, Inc. Announces Reverse Stock Split
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
From Vaccinex, Inc.
Via GlobeNewswire
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
Pepinemab, anti-SEMA4D blocking antibody, appears to enhance clinical activity of immune checkpoint inhibitors via induction of highly organized tertiary immune structures in tumors of patients with... 
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
Pepinemab, anti-SEMA4D blocking antibody, appears to inhibit astrocyte activation and brain inflammation as evidenced by significantly reduced levels of GFAP in patient blood 
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Announces Pricing of $9.6 Million Public Offering
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex, Inc. Announces Reverse Stock Split
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian Cells
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Announces Private Placement with Commitments of $5.0 Million
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference
March 24th presentation to highlight learnings related to pepinemab’s mechanism of action in both Huntington’s Disease and Alzheimer’s Disease 
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis
From Vaccinex, Inc.
Via GlobeNewswire
MarketBeat Week in Review – 2/6 - 2/10
Markets are closed the week looking for direction as investors believe a soft landing is not possible and higher interest rates are likely 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Economy Interest Rates
Should Investors Buy or Sell the Vaccinex Patent News?
Shares of Vaccinex, Inc. are higher on February 7 on news that the clinical-stage biotechnology company secured a patent. Is it time to buy or sell the news? 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology
Surface Oncology initiates clinical trial with antibody discovered using Vaccinex’s ActivMAb® Antibody Discovery Platform 
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Announces $3.8 Million Private Placement
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update
Continued Progress in Pepinemab Oncology and Neurology Clinical Programs 
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer
New Biomarkers of Response and Resistance that Suggest Pepinemab Could Offer New Combination Treatment Options 
From Vaccinex, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.